These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38539416)

  • 1. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
    Biselli M; Reggidori N; Iavarone M; Renzulli M; Lani L; Granito A; Piscaglia F; Lorenzini S; Alimenti E; Vara G; Caraceni P; Sangiovanni A; Marignani M; Gigante E; Brandi N; Gramenzi A; Trevisani F
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment.
    Antonelli G; Gigante E; Iavarone M; Begini P; Sangiovanni A; Iannicelli E; Biondetti P; Pellicelli AM; Miglioresi L; Marchetti P; Lampertico P; Marignani M
    United European Gastroenterol J; 2018 Aug; 6(7):1039-1048. PubMed ID: 30228892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
    PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.
    Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
    Oncol Lett; 2017 Aug; 14(2):1637-1647. PubMed ID: 28789390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma.
    Meza-Junco J; Montano-Loza AJ; Baracos VE; Prado CM; Bain VG; Beaumont C; Esfandiari N; Lieffers JR; Sawyer MB
    J Clin Gastroenterol; 2013; 47(10):861-70. PubMed ID: 23751844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
    Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
    PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sarcopenia on Two-Year Mortality in Patients with HCV-Associated Hepatocellular Carcinoma After Radiofrequency Ablation.
    Salman A; Salman M; Moustafa A; Shaaban HE; El-Mikkawy A; Labib S; Youssef A; Omar MG; Matter M; Elkassar H
    J Hepatocell Carcinoma; 2021; 8():313-320. PubMed ID: 33954153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis.
    Montano-Loza AJ; Duarte-Rojo A; Meza-Junco J; Baracos VE; Sawyer MB; Pang JX; Beaumont C; Esfandiari N; Myers RP
    Clin Transl Gastroenterol; 2015 Jul; 6(7):e102. PubMed ID: 26181291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.
    Yamasaki T; Saeki I; Yamauchi Y; Matsumoto T; Suehiro Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Takami T; Chayama K; Kato N; Sakaida I
    Liver Cancer; 2022 Jul; 11(4):329-340. PubMed ID: 35978601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline.
    Ye Z; Saraf A; Ravipati Y; Hoebers F; Zha Y; Zapaishchykova A; Likitlersuang J; Tishler RB; Schoenfeld JD; Margalit DN; Haddad RI; Mak RH; Naser M; Wahid KA; Sahlsten J; Jaskari J; Kaski K; Mäkitie AA; Fuller CD; Aerts HJWL; Kann BH
    medRxiv; 2023 Mar; ():. PubMed ID: 36945519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
    Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
    Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Omiya S; Komatsu S; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Sofue K; Yano Y; Sakai Y; Yanagimoto H; Toyama H; Ajiki T; Fukumoto T
    Anticancer Res; 2021 Nov; 41(11):5775-5783. PubMed ID: 34732451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
    Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
    J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
    Xiong B; Fu B; Wu Y; Gao F; Hou C
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia as a Predictive Factor for Recurrence of Hepatocellular Carcinoma Following Radiofrequency Ablation.
    Jaruvongvanich V; Thamtorawat S; Saiviroonporn P; Pisanuwongse A; Siriwanarangsun P
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1143-1150. PubMed ID: 37116135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed Tomography-Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolization: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles.
    Wu CH; Ho MC; Chen CH; Liang JD; Huang KW; Cheng MF; Chang CK; Chang CH; Liang PC
    Liver Cancer; 2023 Dec; 12(6):550-564. PubMed ID: 38058418
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis.
    Begini P; Gigante E; Antonelli G; Carbonetti F; Iannicelli E; Anania G; Imperatrice B; Pellicelli AM; Fave GD; Marignani M
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):107-114. PubMed ID: 28051799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.